Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DACLIZUMAB Cause Multiple organ dysfunction syndrome? 18 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Multiple organ dysfunction syndrome have been filed in association with DACLIZUMAB. This represents 0.6% of all adverse event reports for DACLIZUMAB.

18
Reports of Multiple organ dysfunction syndrome with DACLIZUMAB
0.6%
of all DACLIZUMAB reports
18
Deaths
6
Hospitalizations

How Dangerous Is Multiple organ dysfunction syndrome From DACLIZUMAB?

Of the 18 reports, 18 (100.0%) resulted in death, 6 (33.3%) required hospitalization, and 4 (22.2%) were considered life-threatening.

Is Multiple organ dysfunction syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DACLIZUMAB. However, 18 reports have been filed with the FAERS database.

What Other Side Effects Does DACLIZUMAB Cause?

Alopecia (450) Transplant dysfunction (421) Transplant rejection (385) Acne (382) Ovarian cyst (374) Multiple sclerosis relapse (313) Drug ineffective (229) Pain (224) Pneumonia (213) Condition aggravated (172)

What Other Drugs Cause Multiple organ dysfunction syndrome?

TACROLIMUS (1,847) CYCLOPHOSPHAMIDE (1,597) MYCOPHENOLATE MOFETIL (1,566) PREDNISONE (1,525) DEXAMETHASONE (1,355) METHOTREXATE (1,317) METHYLPREDNISOLONE (1,278) RITUXIMAB (1,188) PREDNISOLONE (1,154) CYCLOSPORINE (933)

Which DACLIZUMAB Alternatives Have Lower Multiple organ dysfunction syndrome Risk?

DACLIZUMAB vs DACOMITINIB DACLIZUMAB vs DACTINOMYCIN DACLIZUMAB vs DALBAVANCIN DACLIZUMAB vs DALFAMPRIDINE DACLIZUMAB vs DALTEPARIN

Related Pages

DACLIZUMAB Full Profile All Multiple organ dysfunction syndrome Reports All Drugs Causing Multiple organ dysfunction syndrome DACLIZUMAB Demographics